A total of 215 drugs for heart disease and stroke are awaiting FDA approval or are in clinical trials, according to a PhRMA report. The lineup includes 30 for heart failure, 29 for lipid disorders, 19 for stroke and 17 for hypertension. "The cardiovascular therapies in the pipeline reflect the commitment of America's biopharmaceutical research companies to build on the progress made to date and help patients lead longer and healthier lives," PhRMA President and CEO John J. Castellani said.

Related Summaries